Sulodexide reduces senescence-related changes in human endothelial cells

Medical Science Monitor

Volumn 17, Issue 4, 2011, Pages 222-226

  Suminska Jasinska, Katarzyna ^a   Polubinska, Alicja ^a   Ciszewicz, Marta ^a   Mikstacki, Adam ^a   Antoniewicz, Artur ^a   Breborowicz, Andrzej ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Endothelial cells; Senescence; Sulodexide

Indexed keywords

BETA GALACTOSIDASE; CYTOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; SULODEXIDE;

ARTICLE; CELL AGING; CELL CULTURE; CELL DIVISION; CELL POPULATION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; ENDOTHELIUM CELL; ENZYME ACTIVITY; HEALING; HUMAN; HUMAN CELL; IN VITRO STUDY; OXIDATIVE STRESS;

EID: 79953673209     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/msm.881719     Document Type: Article

References (29)

1. Nenci GG: Dermatan sulphate as an antithrombotic drug. Pathophysiol Haemost Thromb, 2002: 32: 303-7
2. Diabetic Albuminuria Vessel Tunisia Study Investigators D, Blouza S, Dakhli S, Abid H et al: Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. J Nephrol, 2010; 23: 415-24
3. Crepaldi G, Fellin R, Calabro A et al: Preliminary results of sulodexide treatment in patients with peripheral atherosclerosis and hyperlipidemia. A multicenter trial. Monogr Atheroscler, 1986; 14: 215-21
4. Lauver DA, Booth EA, White AJ et al: Sulodexide attenuates myocardial ische-mia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis. J Pharmacol Exp Ther, 2005: 312: 794-800
5. Kristová V, Kriska M, Babál P et al: Evaluation of endothelium-protective effects of drugs in experimental models of endothelial damage. Physiol Res, 2000; 49: 123-28
6. Kristová V, Lísková S, Sotníková R et al: Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats. Physiol Res, 2008; 57: 491-94
7. Borawski J, Gozdzikiewicz J, Dubowski M et al: Tissue factor pathway inhibitor release and depletion by sulodexide in humans. Adv Med Sci, 2009; 54: 32-36
8. Borawski J, Dubowski M, Pawlak K, Mysliwiec M: Sulodexide induces hepatocyte growth factor release in humans. Europ J Pharmacol, 2007; 558: 167-71
9. Ciszewicz M, Połubinska A, Antoniewicz A et al: Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity. Transl Res, 2009; 153: 118-23
10. Karon J, Połubinska A, Antoniewicz Aa et al: Anti-inflammatory effect of sulodexide during acute peritonitis in rats. Blood Purif, 2007; 25: 510-14
11. Csiszar A, Wang M, Lakatta EG, Ungvari Z: Inflammation and endothelial dysfunction during aging: role of NF-kB. J Appl Physiol, 2008; 105: 1333-41
12. Hayflick L, Moorhead PS: The serial cultivation of human diploid cell strains. Exp Cell Res, 1961; 25: 585-21
13. Erusalimsky JD, Kurz DJ: Cellular senescence in vivo: its relevance in ageing and cardiovascular disease. Exp Gerontology, 2005; 40: 634-42
14. Ksia{ogonek}żek K, Piwocka K, Brzezinska A et al: Early loss of proliferative potential of human peritoneal mesothelial cells in culture: the role of p16(INK4a)-mediated premature senescence. J Appl Physiol, 2006; 100: 988-95
15. Foreman KE, Tang J: Molecular mechanisms of replicative senescence in endothelial cells. Exp Geront, 2003; 38: 1251-57
16. Fenton M, Barker S, Kurz DI, Erusalimsky JD: Cellular senescence after single and repeated balloon catheter denudations of rabiit carotid artery. Arterioscler Thromb Vasc Biol, 2001; 21: 220-26
17. Csiszar A, Podlutsky A, Wolin MS et al: Oxidative stress and accelerated vascular aging: implications for cigarette smoking. Front Biosc, 2009; 14: 3128-44
18. Versari D, Daghini E, Virdis A et al: The ageing endothelium, cardiovascular risk and disease in man. Exp Physiol, 2009; 94: 317-21
19. DiFrancescomarino S, Sciartilli A, Di VAlerio V et al: The effect of physical exercise on endothelial function. Sports Med, 2009; 39: 797-812
20. Killilea DW, Maier JAM: A connection between magnesium deficiency and aging: a new insights from cellular studies. Magnes Res, 2008; 21: 77-82
21. Kondo T, Hirose M, Kageyama K: Roles of oxidative stress and redox regulation in atherosclerosis. J Atheroscler Thromb, 2009; 16: 532-38
22. Van der Loo B, Schildknecht S, Zee R, Bachschmid MM: Signalling processes in en-dothelial againg in relation to chronic oxidative stress and their potential therapeutic implications in humans. Exp Physiol, 2008; 94: 305-10
23. Skrha J, Perusicova J, Kvasnicka J, Hilgertova J: The effect of glycosaminoglycan su-lodexide on oxidative stress and fibrinolysis in diabetes mellitus. Sb Lek, 1998; 99: 103-9
24. Bilinska M, Wolszakiewicz J, Duda M et al: Antioxidative activity of sulodexide, a glycosaminoglycan, In patients with stable coronary artery disease: a pilot study. Med Sci Monit, 2009: 15(12): CR618-23
25. Fernandes AN, Rodriguez-Losada N, Jimenez-Navarro MF et al: Stimulation of endo-thelial progenitor cells: a new putative effect of several cardiovascular drugs. Eur J Clin Pharmacol, 2010; 66: 219-30
26. Preiss DJ, Sattar N: Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis? Int J Clin Pract, 2007; 61: 697-701
27. Narsh KN: Pathobiology of atherosclerosis-a brief review. Semin Thromb Hemost, 2004; 30: 665-72
28. Ogami M, Ikura Y, Ohsawa M et al: Telomer shortening in human coronary artery diseases. Arteriscler Thromb Vasc Biol, 2004; 24: 546-50
29. Minamino T, Miyauchi H, Yoshida T et al: Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation, 2002; 105: 1541-44